A detailed history of Neuberger Berman Group LLC transactions in Argenx Se stock. As of the latest transaction made, Neuberger Berman Group LLC holds 703 shares of ARGX stock, worth $441,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
703
Previous 647 8.66%
Holding current value
$441,708
Previous $278,000 37.05%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $24,316 - $30,906
56 Added 8.66%
703 $381,000
Q2 2024

Nov 14, 2024

SELL
$356.01 - $451.55 $70,133 - $88,955
-197 Reduced 23.34%
647 $278,000
Q2 2024

Aug 13, 2024

SELL
$356.01 - $451.55 $70,133 - $88,955
-197 Reduced 23.34%
647 $278,000
Q1 2024

Nov 14, 2024

SELL
$356.95 - $413.29 $13,207 - $15,291
-37 Reduced 4.2%
844 $332,000
Q1 2024

May 13, 2024

BUY
$356.95 - $413.29 $301,265 - $348,816
844 New
844 $332,000
Q4 2023

Nov 14, 2024

BUY
$338.91 - $506.01 $79,304 - $118,406
234 Added 36.17%
881 $335,000
Q4 2023

Feb 09, 2024

BUY
$338.91 - $506.01 $298,579 - $445,794
881 New
881 $335,000
Q1 2023

May 12, 2023

SELL
$334.23 - $403.65 $7.01 Million - $8.46 Million
-20,959 Reduced 60.68%
13,583 $5.06 Million
Q4 2022

Feb 13, 2023

BUY
$342.17 - $402.31 $2,395 - $2,816
7 Added 0.02%
34,542 $13.1 Million
Q3 2022

Nov 15, 2022

BUY
$343.2 - $395.75 $6,177 - $7,123
18 Added 0.05%
34,535 $12.2 Million
Q2 2022

Aug 15, 2022

BUY
$269.58 - $378.88 $541,047 - $760,412
2,007 Added 6.17%
34,517 $13.1 Million
Q1 2022

May 13, 2022

SELL
$254.45 - $351.06 $508 - $702
-2 Reduced 0.01%
32,510 $10.2 Million
Q4 2021

Feb 11, 2022

BUY
$272.01 - $353.03 $8.84 Million - $11.5 Million
32,512 New
32,512 $11.4 Million
Q1 2019

May 13, 2019

SELL
$98.85 - $134.59 $1.09 Million - $1.48 Million
-11,000 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$63.81 - $109.82 $701,910 - $1.21 Million
11,000 New
11,000 $1.06 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.